Kate Haviland, Blueprint Medicines CEO
What bear market? Blueprint lines up $1.25B to expand labels, maybe tack on more drugs
As it works to pad the case for expanding its Ayvakit and Gavreto labels, Blueprint Medicines has lined up $1.25 billion in funding, with some …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
